Biopharma Daily Stock Updates - 01/07/21

Updated: Jan 13

$XBI $149.21 (+4.11%) 📈


$NVAX (+3.56%) - Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine


$SRPTA (+1.50%) - Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

$ALNY (+9.91%) - Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

$MRUS (-1.16%) - Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

$GLYC (+4.32%) - APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

$ALDX (+26.42%) - Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

$BTNX (+2.78%) - BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

$AQST (+3.25%) - Aquestive Therapeutics Provides Business Update

$DVAX (+6.52%) - Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

$KALA (+3.96%) - Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

$LOGC (+1.85%) - LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

$PRAX (+4.62%) - Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs


$CERC (+2.11%) - Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

$ARCT (+35.65%) - Wells Fargo Initiates Coverage On Arcturus Therapeutics with Overweight Rating

$AMRN (+9.69%) - Amarin Provides Preliminary 2020 Results and 2021 Outlook

$EIGR (-8.06%) - Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans

$RVNC (+8.79%) - Revance Provides Corporate Update and Anticipated Milestones for 2021


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.